The Foundation has awarded $100,000 to The Children’s Cancer Therapy Development Institute (cc-TDI) in support of DIPG research. The cc-TDI team of Drs Xiaolei Lian, Noah Berlow and Charles Keller is working to develop an antibody-drug conjugate (ADC) for DIPG.
The limited response of DIPG to widely used therapeutic classes necessitates the development of novel treatments. One such treatment that can be rapidly translated to the clinic is an antibody-drug conjugate (ADC). ADCs are a class of immunoconjugates which chemically link protein-specific antibodies with cytotoxic agents to target antigen-expressing cells with high specificity. ADCs enable specific targeting of the Interleukin-13 cell surface receptor (IL13Rα2) abundantly expressed in DIPG cells but notably absent in surrounding normal brain tissue while avoiding the life-threatening immune inflammatory responses induced by immune-modulating therapies.
Our support enables cc-TDI researchers to optimize a pre-clinically validated IL13Rα2-targeting antibody-drug conjugate (ADC) for rapid clinical translation.
Please access www.cc-tdi.org for more information on The Children’s Cancer Therapy Development Institute.